The Advanced Addiction Psychopharmacology Course is Going Virtual!

Save the date: Saturday, November 7, 2020 and Saturday, November 14, 2020

View Presenter Financial Disclosure Information

Who Should Attend?

This intensive, 12-hour, online course is designed for physicians and other health care professionals who have a foundation in prescribing medication for patients with substance use disorders, including those with co-occurring psychiatric conditions, but would like a deeper understanding of these pharmacotherapies. The Advanced Addiction Psychopharmacology Course will consist of two complementary components, including 9 on-demand video presentations, followed by a 2-day series of live webinar case discussions and Q&A sessions held on Saturday, November 7th from 12:00pm – 3:35pm ET and Saturday, November 14th from 12:00pm – 4:00pm ET. Course participants can earn up to 12 AMA PRA Category 1 Credits™.

Joint Accreditation

View Continuing Education Credits

Educational Objectives

This course is designed for learners with a foundational knowledge of addiction psychiatry will who wish to receive a more in-depth educational training in addiction psychopharmacology.

After participating in this course, learners should be able to:

  • Describe how to use methadone, buprenorphine and naltrexone in clinical practice for the treatment of opioid use disorders.
  • Describe medication treatments for alcohol use disorders.
  • Determine when to use varenicline, bupropion, and nicotine replacement therapy (NRT) for treatment of nicotine use disorder.
  • Discuss new evidence-based medication treatments for cocaine and methamphetamine use disorder.
  • Discuss new evidence-based medication treatments for cannabis use disorder.
  • Discuss medication approaches for the treatment of sedative-hypnotic use disorder.
  • List evidence-based options for anti-depressant and anti-anxiety pharmacotherapy when treating patients with a co-occurring substance use disorder.
  • Discuss evidence-based pharmacotherapy for treatment of ADHD with co-occurring substance use disorders.
  • Discuss the pharmacotherapy of bipolar disorder in patients with co-occurring substance use disorder.